Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company's lead drug candidate, LYR-210, offers a novel approach for directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy.
Market
Ear, Nose and Throat (ENT) diseases
Location
Watertown,
MA,
USA
Coinvestors
ArrowMark Partners, Perceptive Advisors, RA Capital Management, Soleus Capital